Trastuzumab beyond progression in HER2-positive metastatic breast cancer

被引：1
|
作者：
Al-Naqqash, Manwar [1 ,2 ]
Jasim Al-Serarati, Waleed [3 ]
Farooq Kareem, Tara [4 ]
机构：
[1] Univ Baghdad, Dept Surg, Coll Med, Baghdad 10001, Iraq
[2] Minist Hlth Environm, Dept Radiat Oncol, Oncol Teaching Hosp, Baghdad Med City Complex, Baghdad, Iraq
[3] Minist Hlth & Environm, Dept Oncol, Baghdad Med City Complex, Baghdad, Iraq
[4] Minist Hlth & Environm, Oncol Teaching Hosp, Dept Diagnost Radiol, Baghdad Med City Complex, Baghdad, Iraq
来源：
BREAST JOURNAL | 2021年 / 27卷 / 03期
关键词：
breast cancer; HER2; neu; time to progression; trastuzumab;
D O I：
10.1111/tbj.14157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [41] Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer
    Metro, G.
    Fabi, A.
    Giannarelli, D.
    Gemma, D.
    Ciccarese, M.
    Lanzetta, G.
    Papaldo, P.
    Lorusso, V.
    Magnolfi, E.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [43] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [44] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [45] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [46] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [47] In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer
    Wang, Hui
    Nie, Caiyun
    Xu, Weifeng
    Li, Jing
    Gou, He
    Lv, Huifang
    Chen, Beibei
    Wang, Jianzheng
    Liu, Yingjun
    He, Yunduan
    Zhao, Jing
    Chen, Xiaobing
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [48] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [49] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04): : 219 - 220
  • [50] Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study
    Hammerman, Ariel
    Greenberg-Dotan, Sari
    Feldhamer, Ilan
    Bitterman, Haim
    Yerushalmi, Rinat
    PLOS ONE, 2015, 10 (09):
12345